The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
1037 ET - GSK is poised to deliver growth in core earnings per share every year over the coming decade, as the loss of a key HIV patent should have less of an impact than many fear, Bernstein analysts say in a research note. The U.K. drugmaker is developing three new HIV products that should improve its sales prospects in the first half of the 2030s, according to Bernstein. The new products and the difficulty of manufacturing cabotegravir, the active ingredient in HIV drugs that is due to lose U.S. patents in 2029 and 2030, means the sales erosion from the patent should be less pronounced than expected, the analysts ay. Bernstein says it raises its core EPS forecast for GSK over the 2026-35 period by up to 25% and now projects growth every year. Shares rise 1.7%. (adria.calatayud@wsj.com)
0817 ET - Fresenius Medical Care investors might be disappointed by a smaller-than-expected increase in 2027 payment rates proposed by the U.S. Centers for Medicare & Medicaid Services, UBS analysts say in a research note. The CMS on Wednesday said it proposed to increase payments to facilities where Medicare beneficiaries with end-stage renal disease get dialysis services by 1.1% next year. The proposed raise for the base rate is roughly half of what investors likely anticipated and well below prior years, according to UBS. Shares in Fresenius Medical Care fall 2.8%. (adria.calatayud@wsj.com)
0205 ET - HIV treatments look set to undergo a major transformation in the coming decades, and GSK's potential in this market seems underappreciated, Bernstein analysts say in a research note. With Britain's GSK and American rival Gilead Sciences commanding a combined 90% share of the U.S. HIV market, this is essentially a duopoly, according to Bernstein. Existing HIV drugs are already very effective, but upcoming innovations that will help move patients to long-acting injectable drugs from daily tablets is expected to drive future market growth, the analysts say. The U.S. HIV market is expected to grow to $37 billion in 2040, up from $26 billion last year, with GSK's share projected to rise to 44% from 26% over the same time horizon, they estimate. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
June 25, 2026 12:20 ET (16:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments